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The most distinguishing and earliest  common immunological abnormality shared 
by  all  three  murine  models  of accelerated  systemic  lupus  erythematosus  (SLE), 1 
MRL/I, BXSB males, and NZB ×  NZW females is B cell hyperactivity (1,  2).  These 
hyperactive  B  lymphocytes express  (a)  early  spontaneous  polyclonal  activation,  (b) 
increased frequency of colony formation and Ig secretion, and (c) excess autoantibody 
production. These features are present early in the mice with accelerated SLE but not 
in  their  late  life  SLE-prone  counterparts  (female  MRL/n,  BXSB,  NZW)  or  in 
immunologically  normal  routine  strains  (BALB/c  and  C57BL/6).  The  underlying 
mechanisms responsible for this early, generalized B cell activation and autoantibody 
production are not known but presumably could involve intrinsic B cell abnormalities, 
regulatory cell defects, or excessive actions of one or more endogenous or exogenous 
B cell stimulators. 
Lipopolysaccharide (LPS), derived from gram-negative bacteria, is a potent in vivo 
and  in  vitro  stimulator  of B  lymphocytes  and  may  be  considered  a  prototype  of 
exogenous predominantly  T-independent  polyclonal  B  cell  activator  (PBA)  (3).  In 
the  absence  of any  specific  antigenic  influence,  LPS  can  trigger  proliferation  and 
differentiation  of B  lymphocytes with production  of Ig and autoantibodies.  A  single 
injection  of LPS  into normal  mice will  lead  to transient  formation  of autoantigen- 
antibody  immune  complexes  both  within  the  circulation  and  also  as  deposits  in 
glomeruli but without the development of histologically detectable glomerulonephritis 
(GN)  (4,  5).  Furthermore,  the  lipid  A  portion  of  LPS,  which  is  mitogenic  and 
minimally  antigenic  (6),  can  induce  long-lasting  production  of both  lgM  and  IgG 
autoantibodies  (6-8). 
The purpose of our present study was to examine the pathogenic potential  of such 
exogenously-induced autoimmunity  by asking the  questions:  (a)  Can chronic B  cell 
activation alone induce significant autoimmune disease  (AID)? and  (b)  What role(s), 
if any, might a genetically-determined  host predisposition play in the development of 
such disease? We found that chronic stimulation with the nonantigenic but mitogenic 
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lipid A  fraction  of LPS,  beginning early in  life, can  greatly accelerate the onset  of 
late-life SLE disease of MRL/n,  BXSB, and NZW females, as evidenced by the early 
increase of Ig-secreting splenoeytes, hypergammaglobulinemia, autoantibody produc- 
tion, and fatal immune complex-mediated GN. Similar chronic mitogen stimulation 
had less effect in immunologically normal mice which developed a  much milder form 
of AID and no effect in LPS nonresponder C3H/HeJ  mice. 
Materials  and  Methods 
Mice.  Alt mice used  in  this study were 6-10  wk old.  Late-life SLE-prone mice  (female 
MRL/n, BXSB, and NZW), normal mice (BALB/c and C57BL/6 females), and LPS nonre- 
sponder mice C3H/HeJ  (9) were all obtained from the routine breeding colony of the Scripps 
Clinic and Research Foundation. 
Lipid A-LPS (R595).  Lipid A-LPS purified from Salmonella minnesota was purchased from 
Calbiochem-Behring Corp., American Hoechst Corp., La Jolla, CA. The R595  preparations 
were diluted to  125 #g/ml with saline for injection. All six groups of mice were given 25/tg 
R595 in a 0.2 ml vol i.p. twice a week beginning at 6 wk of age. 
Heparin.  Heparin  Sodium  Injectable, purchased  from  Invenes  (Chagrin  Falls, OH)  was 
used for anticoagulation to rule out possible thrombotic complications (Schwartzman reaction) 
induced by the LPS endotoxin, which might contribute to tissue injury. Additional represent- 
ative groups of mice, both late-life, SLE-prone (MRL/n), and non-SLE (BALB/c, C3H/HeJ) 
strains received  1 U  of heparin/g body weight, subcutaneously, 30  min  before each  R595 
injection. The effectiveness of heparinization was tested by measuring the whole blood clotting 
time of the treated mice sampled at 30 rain after R595 injections. 
Serological assays.  Anti-single-strand DNA (ssDNA) antibody activity was determined by a 
modified Farr DNA-binding radioimmunoassay (10). Circulating immune complexes (CIC) in 
individual sera were quantitated by two different assays: (a) a modified Raji cell radioimmu- 
noassay using aggregated mouse gammaglobulin (AMG) to prepare the standard curve (11), 
and (b) Ig-bound retroviral envelope gp70 complexes, expressed as micrograms of gp70 bound 
to Ig detected by absorption of sera with staphylococcal protein A  (12)  (Calbiochem-Behring 
Corp.). Serum levels of IgM, IgGl, IgG2a, and IgG2b were determined by radial immunodif- 
fusion (13)  in commercially prepared agar plates (Meloy Laboratories Inc., Springfield, VA) 
containing rabbit anti-mouse isotype and subclass specific antisera; IgG3 levels were similarly 
assessed using monospecific rabbit-anti-mouse antisera (Litton Bionetics, Kensington, MD). 
Blood urea nitrogen (BUN) levels were semiquantitatively measured with Azostix (Ames Div., 
Miles Laboratory Inc., Elkhart, IN) with values ranging from 0.1 to 0.6 mg/ml. BUN levels of 
>0.3 mg/ml were considered as indications of compromised renal function. 
Splenic Lymphocyte Plaque Assay.  Spleen cells secreting IgG1, IgG2a, IgG2b, IgG3, and IgM 
were detected with subclass-specific facilitating antisera used in a  reverse plaque assay using 
protein A-coupled sheep erythrocytes (SRBC) (14). Pooled spleen cells of four to six mice from 
each of the six  R595-treated  groups  and  their corresponding unmanipulated  controls were 
tested after 2 and 4 mo of R595 treatment for quantitation of plaque-forming cells (PFC). The 
facilitating antibodies used in this study were purchased from Gateway Immunosera, Cahoka, 
IL, and rendered subclass specific by solid-phase immunoadsorption. Specificity and efficiencies 
of the  facilitating  antisera  were  verified  using  a  panel  of  mouse  plasmacytomas  and/or 
hybridomas secreting antibodies of the  major mouse  Ig isotypes. Facilitating antisera were 
diluted -1:2,000 to give near optimal plaquing efficiencies. 
Histopathology.  Representative mice from each group were autopsied at bimonthly intervals 
and sections of major organs were processed and stained with PAS for histological examination. 
GN was quantitated on a  1 to 4+ scale based on the severity and extent of histopathological 
changes. A grade 1 lesion showed minimal mesangial thickening, 2+ lesions contained noticeable 
increases in both mesangium and in glomerular cellularity, 3+ lesions were characterized by 
the preceeding features plus superimposed inflammatory exudates and/or capsular adhesions, 
and 4+ lesions had obliteration of glomerular architecture involving ~70%  glomeruli. Grade 
3-4+ GN were considered significant contributors to cause of death resulting from autoimmune 
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Other  histological  manifestations  of autoimmune  disease  were  also  evaluated  and  docu- 
mented. They included (a) lymphoproliferation, measured by the total increased area of splenic 
white pulp as compared with unmanipulated controls; (b) degenerative vascular disease (DVD), 
defined as presence of PAS  + deposits along and within coronary vessel walls and lumens;  and 
(c)  arteritis,  identified  by presence  of necrotizing and  exudative  inflammation  involving the 
walls of small to medium sized arteries. 
Detection of Ig and Fibrinogen Deposits in Renal  Glomeruli.  One-half of each  kidney  obtained 
from mice of the various groups at autopsy was frozen in liquid nitrogen and stored at -70°C. 
Frozen  sections  were  cut  and  processed  for staining  with  fluorescein  isothiocyanate  (FITC) 
rabbit-anti-mouse  IgG and goat anti-mouse fibrinogen  (N. L. Cappel  Laboratories,  Cochran- 
ville, PA). The intensities of fluorescence within renal glomeruli were graded from 0 to 4+. 
Detection of Fibrinogen Degradation Products (FDP).  To  identify  possible  endotoxin-induced 
coagulopathy as a  result of the repeated  R595  injections, plasma  from individual mice at  1 h 
pre- and  I, 2, and 24 h post-R595 injections were obtained and analyzed for presence of FDP. 
FDP  were detected  by  immunoelectrophoresis  based  on  their  enhanced  mobility relative to 
intact  fibrinogen  (15).  Mouse  fibrinogen  was  isolated  from  plasma  by  differential  ethanol 
precipitation  (16)  and  antiserum  to  fibrinogen  was  raised  in  rabbits.  The  antiserum  was 
rendered specific for fibrinogen by absorption with freshly prepared mouse serum (I part mouse 
serum  to  50  parts  rabbit  antiserum).  Immunoelectrophoresis  was  performed  in  1%  agarose 
(SeaKem ME; Marine Colloids, Rockville, MD)  in 0.03 M  sodium barbital,  pH 8.3 on 2 ×  3- 
inch  glass  slides.  5  p,l  plasma  samples  were  applied  and  electrophoresed  at  150  V  for  8  h. 
Troughs were then removed, 50/~1  antiserum  was added,  and  precipitin lines were developed 
at  4°C for 24 h.  Based on  positive controls  developed by the addition  of plasmin  to isolated 
mouse fibrinogen or mouse plasma, the experimental samples were recorded as plus or minus. 
The sensitivity of the system was estimated to be ~50/,tg FDP/ml. 
Results 
Induction  of Autoantibody  Production  by R595.  Table  I  displays  the various serological 
parameters  of the six different  groups  of mice at  5  mo of age,  after  3  mo of chronic 
stimulation  with  R595.  As  compared  with  the  unmanipulated  controls,  all  treated 
groups  except  the  C3H/HeJ  had  hypergammaglobulinemia  and  increased  anti- 
ssDNA  antibodies.  Similarly,  CIC,  measured  by  the  Ig-bound  retroviral  gp70  and 
TABLE  I 
Serological Parameter of R595-treated Mice and Unmampulated Controls 
(5 Mo of Age) 
Percent 
R595  Total Ig  binding  Ig bound  Raft cell 
treatment  anti-  gp70  assay 
ssDNA 
mg/ml  #g/ml  Ilg AMG/ml 
MRL/n ~  +  19  50  22.8  70 
-  5  34  1.6  12 
BXSB ~  +  18  63  17.0  89 
--  4  15  1.0  5 
NZW ~  +  15  46  11.1  37 
--  4  15  3.0  4 
BALB/c2  +  22  48  1.4  22 
--  5  10  0.2  <1 
C57BL/6C2  +  18  34  1.8  25 
--  3  4  0,3  <1 
C3H/HeJ9  +  4  6  0.4  <z 1 
-  4  5  0.2  <1 HANG ET AL.  877 
TABLE II 
IgM and IgG Subclass Responses (PFC) in R595-treated Mice and Unmanipulated Controls 
(4 Mo of Age) PFC ×  103/Spleen 
R595 
treatment  IgG3  IgGl  IgG2a  IsG2b  IgM 
MRL/n  +  466  37  50  98  2369 
-  14  (33)*  4  (9)  6  (8)  11  (9)  80  (30) 
BXSB ~2  +  486  37  39  525  1700 
--  4  (120)  8  (5)  8  (5)  9  (58)  130  (23) 
NZW~  +  189  (i9)  77  (5)  138  .  (34)  60  (12)  3625 
-  10  17  4  5  1032  (4) 
87  6875  BALB/c~  +  500  (83)  85  (12)  80  (8)  (8)  (46) 
-  6  7  10  10  150 
C57BL/62  +  496  43  44  258  8125 
-  6  (82)  5  (5)  4  (10)  18  (14)  125  (67) 
C3H/HeJ2  +  5  (1)  4  7  10  200 
-  .5  4  (l)  6.5  (l)  12  (l)  180  (1) 
* Measured as stimulation index (treated/untreated control) of PFC/106 spleen cells. 
Raji  cell  assay,  were  increased  significantly  in  all  groups  except  C3H/HeJ;  the 
absolute amounts of CIC, however, were less in the treated normal groups than in the 
treated late-life SLE mice. 
Polyclonal B  Cell Activation by R595.  The extent of polyclonal B cell activation by 
R595 was assayed by measuring the numbers of splenic lymphocytes secreting IgG of 
the  different  subclasses  and  IgM. Table  II lists  the  PFC  results  obtained  from the 
treated  and  control groups  2  mo after  initiation  of stimulation  (4  mo of age).  All 
treated  mice,  except  C3H/HeJ,  showed  varying  increases  in  numbers  of splenic 
lymphocytes secreting each of the four IgG subclasses and IgM  (as reflected by the 
calculated stimulation indices). The patterns of Ig enhancement differed among the 
individual strains,  i.e.,  BXSB and  C57BL/6 females had  marked increases  in  IgG3 
(120 and 82 times, respectively) and IgG2b (58 and  14 times);  MRL/n and BALB/c 
females had greater increases in IgG3 (33 and 83 times, respectively) than any of the 
other IgG subclasses; and NZW mice had most enhancement of IgG3 and IgG2a. The 
serum  levels  of IgG subclasses,  measured  at  5  mo  of age,  also  indicated  selective 
subclass enhancement in all but the C3H/HeJ mice, with greatest increases in IgG3 
and IgG2b (Table III). 
Induction of Glomerulonephritis with  R595.  After  2  mo  of R595  injections,  all  five 
groups of mice  (except  C3H/HeJ)  showed grade  2+  GN with  BUN levels  ranging 
from 0.1  to 0.3 mg//zl (Fig.  I). After prolonged stimulation  for 6-8 mo, the late-life 
SLE-prone mice had progression of their GN, i.e.,  grade 4+ and BUN of 0.6 mg//tl, 
whereas normal mice showed no significant progression beyond that seen after 2 too. 
None of the unmanipulated controls, at  10 mo of age, had significant BUN elevation 
or GN-associated mortalities.  In contrast, throughout the  10-too course of identical, 
repeated  R595  treatment,  the  C3H/HeJ  mice  had  neither  abnormal  BUN  nor 
histological  evidence  of renal  disease.  By  immunofluorescence, the  intensity  of Ig 
deposits along the glomerular capillaries of the various groups corresponded in general 
to the extent of GN documented by light microscopy. 
Effect of Heparinization in the R595-treated Mice.  After injection of heparin, the whole 
blood  clotting  time  of the  R595  treated  and  nontreated  mice  was  >12  h  vs.  a 878  POLYCLONAL  B  CELL  ACTIVATION  AND  AUTOIMMUN1TY 
TABLE  III 
Serum Levels of lgM and IgG Subclasses in R595-treated Mice and Unrnanzpulated Controls 
(5 Mo of Age) 
R595 
Treat-  IgG3  IgG 1  ]gG2a  IgG2b  IgM 
ment 
mg/ml 
MRL/n9  +  9.6  2.6  1.6  3.7  1.1 
-  0.2  (48)*  1.9  (~)  t.~  (1)  0.7  (5)  0.5  (2) 
BXSB 9  +  3.7  2.4  1.5  9,1  1.7 
-  0.2  (19)  1.8  (1)  1.3  (1)  0.9  (10)  0.2  (9) 
NZW9  +  4.2  1.9  3.0  3.8  1.7 
--  0.2  (21)  1.7  (I)  1.3  (2)  0.5  (8)  0.3  (5) 
BALB/c~?  +  10.5  3.6  1.8  5.2  1,2 
--  0.5  (21)  1.7  (2)  1.4  (1)  0.7  (8)  0.2  (6) 
C57BL/6~  +  0.5  1.7  1,4  11.0  1.25 
--  0.2  (12)  0.9  (2)  0,9  (1)  0.8  (13)  0.18  (10) 
C3H/HeJ2  +  0.8  0.7  0.9  1.4  0.7 
-  0.7  (1)  0.6  (t)  0.8  (t)  1.2  (1)  0.6  (1) 
* Measured as stimulation index (treated/untreated control); ratio rounded to nearest whole number. 
M  ....  MRL/N  BXSB9  NZW  BALB/c C57BL/6  C3H/HeJ  St~a~s 
Average 
rn~ % SUN 
4+ 
r,~ 
= 
N  2+ 
0 
4681010  4681010  4681010  4681010  4681010  4681010 
Age (months) 
Fro.  1,  Induction of GN in various strains of mice by prolonged stimulation with R595. Solid bars 
indicate the mean grade of GN present in the treated mice at each of the time intervals. Hatched 
bars represent the extent of GN seen  in  unmanipulated controls at  10 mo of age. Average BUN 
levels from  these mice at  the different time intervals are shown  near the top of the figure.  Each 
group includes 5-10 mice. 
nonheparinized control time of 2-3 h. The anticoagulated R595 treated  SLE-prone 
and  normal  mice  developed  serological  and  histological  evidence  of autoimmune 
disease at rates and severities similar to those of their nonanticoagulated counterparts 
(data not shown). Fibrinogen degradation products were not detected in the plasma 
of either the heparinized or nonheparinized R595-stimulated mice, when measured at 
I,  2,  and  24  h  after  injection,  indicating  absence  of significant  R595  endotoxin- HANG  ET  AL.  879 
associated coagulopathy. By light microscopy and immunofluorescence, the amount 
of fibrinogen present in the diseased glomeruli of the R595-treated groups with and 
without heparin were similar, closely resembling those seen in the kidneys of  moribund 
early SLE mice. 
Induction of Other Histological  Features of Autoimmunity.  Table IV lists  the incidences 
of  other histological manifestations ofautoimmune disease present in the R595 treated 
mice at autopsy. All mice except the C3H/HeJ had lymphoproliferation as indicated 
by the increased lymphoid mass in their spleens. In addition, the late-life SLE-prone 
mice (MRL/n and BXSB females) developed DVD and myocardial infarcts. Necro- 
tizing arteritis occurred only in R595 treated MRL/n mice. The normal strains had 
no significant vascular or myocardial lesions. 
Discussion 
While several studies have shown that injections of LPS into normal mice can lead 
to  production  of autoantibodies  and  glomerular  depositions  of antigen-antibody 
complexes, including idiotype-antiidiotype forms (17), none of them have documented 
definitive histological or clinical evidence of immune complex disease, i.e., GN and 
vascular lesions. In a previous study, we have shown that a single injection of R595, 
the mitogenic lipid A portion of LPS, in normal mice (C57BL/6) induced a sustained 
polyclonal B cell activation with increased Ig and autoantibody production, both IgM 
and IgG classes, lasting at least 60 d. Our present study has extended these findings 
to demonstrate that prolonged in vivo polyclonal B cell activation with R595 will not 
only  markedly  accelerate  the  onset  of autoimmunity  and  fatal  immune  complex 
disease in late-life SLE-prone murine strains, but will also lead to development of a 
limited form of autoimmune disease in normal mice. The forms, time of onset, and 
course of disease in the R595-treated late life SLE-prone mice resembled closely the 
spontaneous early SLE of their related  MRL/1  females, BXSB males, and  NZB  × 
NZW females. 
Two recent studies  of the effect of chronic LPS stimulation on SLE and normal 
mice carrying the xid gene defect have yielded differing results. Smathers et al.  (18) 
found that chronic LPS administration (similar treatment to that used in this study) 
TABLE IV 
Incidence of Additional Parameters of Autoimmune Diseases in R595-treated Mice 
DVD 
Lymphopro-  Myocardial  Vasculitis 
liferation*  infarction 
Incidence  Severity:~ 
%  %  % 
MRL/n9  2.3  88  3+  48  36 
BXSB 2  5.6  38  3+  31  0 
NZW~?  3.0  80  1  +  0  0 
BALB/cg?  4.6  0  0  0  0 
C57BL/62  3.3  0  0  0  0 
C3H/HeJ2  1.0  0  0  0  0 
* Mean ratio increase of splenic white pulp, treated/untreated. 
:~ Grading  for DVD was done on  a  scale  of 0  to  3+  based  on  examining four consecutive sections of 
individual bisected hearts. Grade 1 contained minimal PAS  ~ deposits along and within one blood vessel 
wall; grade 2 showed PAS  + deposits with lumenal narrowing in two or three coronary vessels; grade 3 
contained four or more affected coronary blood vessels. 880  POLYCLONAL B CELL ACTIVATION AND AUTOIMMUNITY 
to  NZB  x/d-bearing  mice  resulted  in  autoantibody  production,  whereas  similarly 
treated  DBA/2 xid-bearing  mice did  not  make any autoantihodies.  These  findings 
were  interpreted  as  evidence  of the  importance  of genetic  background  (NZB  vs. 
DBA/2)  in the expression of autoimmunity, when exposed to certain environmental 
factors (chronic LPS stimulation).  On the other hand,  Steinberg et al.  (19)  reported 
that similarly treated  (NZB ×  NZW)F1 xid-bearing mice did not  produce autoanti- 
bodies or autoimmune disease in spite of their obvious AID genetic background and 
suggested that the Ly-5  + B lymphocytes (deleted in the xid gene effect) were essential 
in  the  early  life  SLE.  In  contrast,  Ohsugi  et  al.  (20)  found  that  autoantibody 
production can occur in unmanipulated xid-bearing mice without obvious participa- 
tion  of the  Ly-5  +  B  lymphocyte subsets.  These  reports  clearly  indicate  a  lack  of 
concensus  about  the  roles  of Ly-5  ÷  B  lymphocytes  (xid gene  defect)  and  LPS  in 
autoimmunity. 
In  the  present  study  the  distinctly  different  responses  to  R595  demonstrated  by 
these three genetic/immunological backgrounds, i.e., late-life SLE-prone, normal, and 
nonresponder, emphasize the potential roles ofpolyclonal B cell activation and genetic 
predetermination  in  the  genesis and expression of autoimmune  SLE disease.  R595, 
the lipid A-rich portion of LPS is in all likelihood a more effective chronic PBA than 
LPS since  the latter  is antigenic  (21)  and  its efficiency as a  chronic in vivo PBA is 
compromised by the  generation  of anti-LPS  antibodies  in  the  repeatedly  injected 
mice, whereas no antibodies to R595 have been detected (22). Furthermore, the C3H/ 
He.]  mice used  in  this  study  serve as  more appropriate  negative controls  for LPS- 
R595  B  cell  activation  than  xid-bearing  mice  because  they  lack  receptors  for  this 
activator but are not immunodeficient, and are fully capable of responding to other 
PBA (9). The absence of serological and histological features of AID in the chronically- 
treated C3H/HeJ mice seems to confirm that the R595  induced AID in the late-life 
SLE-prone and "normal" strains results specifically from activation of the immune 
system and not from other effects of endotoxin.  In many respects, the R595 induced 
PBA acts similarly to the  natural  accelerating factors operating in  mice with early 
SLE (23).  The lpr gene of the MRL/1  (24)  or the Y chromosome-associated factor of 
the BXSB (25)  are associated with early SLE not only in their usual hosts but also in 
any host with an AID genetic predisposition (23). The effect ofR595 on the expression 
of AID is also almost identical to the effect of chronic lymphocytic choriomeningitis 
infection,  which  accelerates and  makes more severe SLE  in  genetically predisposed 
mice  and  has  relatively  mild  pathologic  consequences  in  immunologically  normal 
mice (26). 
Whether  T  cell  participation  is  required  in  this  R595-induced  autoimmunity 
remains speculative. While T  cells are necessary in the adjuvant effect of LPS  (27), 
R595 has been considered to be a T  cell-independent PBA (28).  In fact, in nude mice, 
R595 is postulated to replace and act as exogenous T  cell help, leading to production 
of all IgG subclasses (29,  30).  We also have preliminary results to indicate that in the 
absence of significant T  cell populations  (neonatal thymectomy), late-life SLE-prone 
and  normal  mice are  capable of responding  to  R595  and  developing autoimmune 
disease (data not shown). 
Finally,  several additional  observations from this  study of PBA induced  autoim- 
munity are worthy of note: 
(a)  The accelerated  SLE in  the treated  MRL/n  mice is not  accompanied by the HANG ET  AL.  881 
characteristic massive  lymphadenopathy seen  in  their early SLE congenic MRL/1 
mice.  This  implies  that  the  T  lymphocyte proliferation  and  associated  increased 
helper activity  (31)  in  the  latter can  be bypassed or replaced by exogenous B  cell 
activation  leading  to  early  and  complete  disease  expression.  In  fact,  neonatally 
thymectomized MRL/I mice treated with R595 developed accelerated autoimmunity 
and GN associated mortality comparable to the unmanipulated controls rather than 
enjoying the prolonged survival characteristic of neonatally thymectomized individ- 
uals (32). 
(b)  The selectivity of end-organ injury (other than GN) in these R595 treated late 
life SLE-prone mice very closely mimics their early SLE counterparts, again implying 
predeterminations by inherent genetic factors in the various manifestations of autoim- 
mune disease. Arteritis, unique to the MRL/I mice (33), is found only in the treated 
MRL/n mice, whereas DVD and myocardial infarcts, occurring in ~20% of MRL/1 
and BXSB males  (34), are detected in both the MRL/n and BXSB females treated 
with  R595,  though at  a  higher frequency. The treated normal mice, again, show a 
resistance  to  these  autoimmune-mediated  vascular  and  myocardial  injuries,  even 
though  they manifest similar magnitudes of lymphoproliferation, Ig, and autoanti- 
body production.  These  vascular  and  selective organ  injuries  could  be  related  to 
subtle qualitative differences (i.e., affinity, subclass specificities, phlogogenicity) in the 
autoantibodies generated by the SLE-prone and normal mice. The qualitative differ- 
ences of these autoantibodies are presently under investigation. 
Summary 
In vivo, prolonged polyclonal activation of B cells by the nonantigenic but potent 
mitogenic lipid A portion of lipopolysaccharide (LPS-R595) resulted in acceleration 
of the late life systemic lupus erythematosus disease of female MRL/n, BXSB, and 
NZW mice, mimicking the time, form, and histopathological features characteristic 
of their early life disease counterparts, i.e., MRL/1 females, BXSB males, and  (NZB 
×  NZW)F1 females. Similar polyclonal B cell activation of"immunologically normal" 
mice has less effect and led to a limited expression ofautoimmune disease. This R595- 
induced  autoimmunity  and  immune  complex-mediated  disease  seemed  to  be  the 
direct  result  of activation  of the  immune  system  and  not  from  other  effects  of 
endotoxin since C3H/HeJ, a strain lacking lymphocyte receptors for LPS-R595, had 
neither serological nor histological evidence of autoimmune disease despite identical 
treatment. 
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